The United States tuberculosis treatment market was valued at USD 935.81 Million in 2025, driven by the rising tuberculosis incidence and increased focus on multidrug-resistant tuberculosis management in the region. The market is anticipated to grow at a CAGR of 5.10% during the forecast period of 2026-2035, with the values likely to reach USD 1538.92 Million by 2035. The market is driven by the availability of established therapies and government programs supporting treatment access. Advancements in rapid diagnostics and drug formulations offer significant opportunities for improved treatment outcomes and early detection, supporting market growth.
Base Year
Historical Period
Forecast Period
The primary driver in the market is the increasing prevalence of multidrug-resistant tuberculosis (MDR-TB), which necessitates more advanced treatment options and higher demand for specialized therapies.
The integration of new diagnostic technologies expanded access to combination therapies, and the growing focus on shortening treatment durations to improve patient compliance and overall treatment efficacy are major trends in the market.
The United States tuberculosis treatment market is shaped by several key pharmaceutical companies specializing in the development and distribution of both innovative and generic anti-tuberculosis drugs, driving competition and improving treatment accessibility.
Compound Annual Growth Rate
5.1%
Value in USD Million
2026-2035
*this image is indicative*
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially spreading to other organs. Tuberculosis treatment involves a prolonged regimen of antibiotics, typically including isoniazid, rifampin, ethambutol, and pyrazinamide. The United States tuberculosis treatment market is driven by rising public health initiatives, diagnostic advancements, and increased focus on multidrug-resistant tuberculosis management.
Rising Tuberculosis Incidence to Accelerate Market Growth in the United States
The increasing incidence of tuberculosis is a significant growth driver in the market. According to the Centers for Disease Control and Prevention (CDC), in March 2023, the country reported 9,633 cases of tuberculosis disease, reflecting a 15.6% rise compared to 2022 and an 8.3% increase from 2019. This highlights the urgent need for enhanced diagnostics, effective treatment regimens, and stronger public health responses, ultimately accelerating the growth of the tuberculosis treatment market in the region.
Some of the notable trends in the market include the introduction of shorter regimens and advancements in drug-resistant tuberculosis therapies.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Therapy
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
First-Line Therapy Expected to Dominate the Market Share
First-line therapy and second-line therapy are the types of therapies in the market. First-line therapy is expected to hold a substantial the tuberculosis treatment market due to its effectiveness, lower cost, and widespread use in treating drug-sensitive tuberculosis cases. Medications such as isoniazid and rifampin remain the standard approach for initial treatment. Increasing early diagnosis and adherence to treatment protocols further contribute to the dominance of first-line therapy.
The market is primarily driven by the West and South regions. The West, with its advanced healthcare infrastructure and higher immigrant population, shows significant market demand. The South, facing a higher disease burden, also contributes notably to market growth through increased public health initiatives and treatment access. These regions are central to addressing tuberculosis effectively.
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson is a global healthcare leader actively involved in the market. In July 2024, the company received full approval from the U.S. FDA and the European Commission for Sirturo (bedaquiline), a key treatment for multidrug-resistant tuberculosis and a major advancement in TB care.
Otsuka Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, is actively involved in tuberculosis treatment research. In March 2024, its U.S. affiliate, Otsuka Pharmaceutical, Inc., based in Princeton, New Jersey, announced promising interim Phase 2b/c trial results for Quabodepistat (QBS), a novel compound potentially reducing tuberculosis treatment duration when combined with delamanid and bedaquiline.
GlaxoSmithKline plc is a major player involved in tuberculosis treatment in the United States. In May 2024, GSK expanded its strategic collaboration with BioVersys to advance alpibectir (BVL-GSK098), a novel anti-tuberculosis drug candidate. This Phase 2a clinical asset targets multidrug-resistant tuberculosis, addressing a critical public health challenge.
Lupin Limited, established in 1968 and headquartered in Mumbai, India, is a global pharmaceutical company actively involved in tuberculosis treatment. In September 2021, Lupin partnered with TB Alliance to manufacture and commercialize pretomanid, part of the BPaL regimen for highly drug-resistant tuberculosis. This collaboration aims to enhance access to advanced TB therapies, including in the United States.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Sanofi, Pfizer Inc., Novartis AG, Merck & Co., Inc., Cipla Ltd., and Macleods Pharmaceuticals Ltd.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Therapy |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share